COMPASS THERAPEUTICS INC (CMPX) Fundamental Analysis & Valuation

NASDAQ:CMPX • US20454B1044

Current stock price

5.415 USD
-0.58 (-9.75%)
At close:
5.43 USD
+0.01 (+0.28%)
Pre-Market:

This CMPX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CMPX Profitability Analysis

1.1 Basic Checks

  • CMPX had negative earnings in the past year.
  • CMPX had a negative operating cash flow in the past year.
  • In the past 5 years CMPX always reported negative net income.
  • CMPX had a negative operating cash flow in each of the past 5 years.
CMPX Yearly Net Income VS EBIT VS OCF VS FCFCMPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -30.28%, CMPX is in the better half of the industry, outperforming 65.50% of the companies in the same industry.
  • CMPX has a Return On Equity of -33.79%. This is in the better half of the industry: CMPX outperforms 72.48% of its industry peers.
Industry RankSector Rank
ROA -30.28%
ROE -33.79%
ROIC N/A
ROA(3y)-30.84%
ROA(5y)-33.12%
ROE(3y)-33.94%
ROE(5y)-36.42%
ROIC(3y)N/A
ROIC(5y)N/A
CMPX Yearly ROA, ROE, ROICCMPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • CMPX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPX Yearly Profit, Operating, Gross MarginsCMPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CMPX Health Analysis

2.1 Basic Checks

  • CMPX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CMPX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CMPX has been increased compared to 5 years ago.
  • CMPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMPX Yearly Shares OutstandingCMPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
CMPX Yearly Total Debt VS Total AssetsCMPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 22.89 indicates that CMPX is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of CMPX (22.89) is better than 88.37% of its industry peers.
  • There is no outstanding debt for CMPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.89
ROIC/WACCN/A
WACC9.53%
CMPX Yearly LT Debt VS Equity VS FCFCMPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 15.02 indicates that CMPX has no problem at all paying its short term obligations.
  • CMPX has a better Current ratio (15.02) than 91.47% of its industry peers.
  • CMPX has a Quick Ratio of 15.02. This indicates that CMPX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 15.02, CMPX belongs to the best of the industry, outperforming 91.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.02
Quick Ratio 15.02
CMPX Yearly Current Assets VS Current LiabilitesCMPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CMPX Growth Analysis

3.1 Past

  • The earnings per share for CMPX have decreased strongly by -16.22% in the last year.
  • The Revenue for CMPX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-16.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 38.33% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.9%
EPS Next 2Y-7.4%
EPS Next 3Y30.22%
EPS Next 5Y38.33%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMPX Yearly Revenue VS EstimatesCMPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
CMPX Yearly EPS VS EstimatesCMPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

1

4. CMPX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CMPX. In the last year negative earnings were reported.
  • Also next year CMPX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPX Price Earnings VS Forward Price EarningsCMPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPX Per share dataCMPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CMPX's earnings are expected to grow with 30.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.4%
EPS Next 3Y30.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CMPX Dividend Analysis

5.1 Amount

  • No dividends for CMPX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CMPX Fundamentals: All Metrics, Ratios and Statistics

COMPASS THERAPEUTICS INC

NASDAQ:CMPX (4/20/2026, 8:00:00 PM)

Premarket: 5.43 +0.01 (+0.28%)

5.415

-0.58 (-9.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-13
Inst Owners79.19%
Inst Owner Change0%
Ins Owners6.82%
Ins Owner Change3.65%
Market Cap975.19M
Revenue(TTM)N/A
Net Income(TTM)-66.49M
Analysts87.27
Price Target13.77 (154.29%)
Short Float %18.04%
Short Ratio12.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.69%
Min EPS beat(2)2.39%
Max EPS beat(2)42.98%
EPS beat(4)2
Avg EPS beat(4)6.77%
Min EPS beat(4)-12.3%
Max EPS beat(4)42.98%
EPS beat(8)4
Avg EPS beat(8)9.41%
EPS beat(12)6
Avg EPS beat(12)10.41%
EPS beat(16)9
Avg EPS beat(16)10.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.19%
PT rev (3m)4.46%
EPS NQ rev (1m)0.72%
EPS NQ rev (3m)10.83%
EPS NY rev (1m)10.21%
EPS NY rev (3m)11.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-28.06%
Revenue NY rev (3m)-22.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.96
P/tB 4.96
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0
BVpS1.09
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -30.28%
ROE -33.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.84%
ROA(5y)-33.12%
ROE(3y)-33.94%
ROE(5y)-36.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.7%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.02
Quick Ratio 15.02
Altman-Z 22.89
F-Score4
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)4.49%
Cap/Depr(5y)74.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y4.9%
EPS Next 2Y-7.4%
EPS Next 3Y30.22%
EPS Next 5Y38.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.46%
EBIT Next 3Y-10.36%
EBIT Next 5Y29.66%
FCF growth 1Y-9.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.56%
OCF growth 3YN/A
OCF growth 5YN/A

COMPASS THERAPEUTICS INC / CMPX Fundamental Analysis FAQ

What is the fundamental rating for CMPX stock?

ChartMill assigns a fundamental rating of 3 / 10 to CMPX.


Can you provide the valuation status for COMPASS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to COMPASS THERAPEUTICS INC (CMPX). This can be considered as Overvalued.


How profitable is COMPASS THERAPEUTICS INC (CMPX) stock?

COMPASS THERAPEUTICS INC (CMPX) has a profitability rating of 1 / 10.